Literature DB >> 33799195

Depressive mood changes are associated with self-perceptions of ADHD characteristics in adults.

Kanako Ishizuka1, Tomomi Ishiguro2, Norio Nomura2, Toshiya Inada3.   

Abstract

Subjective attention deficit/hyperactivity disorder (ADHD) symptoms seen in adult depressive patients have often become a pathophysiological topic in recent years. Screening questionnaires are widely used for detecting ADHD; however, the risk of misdiagnosis exists. The present study examined whether self-perceptions of ADHD-related characteristics were consistent regardless of changes in the severity of depressive symptoms. Between April to October 2018, newly diagnosed depressed outpatients aged 24-59 years with good social functioning and without a history of ADHD were asked to fill out the Adult ADHD Self-Report Scale version 1.1 (ASRS) and the Beck Depression Inventory (BDI) at baseline (n = 726) and 12-week follow-up (n = 202). A statistically significant correlation was found between a change in BDI and ASRS scores (score at baseline minus score at the endpoint; r = .57). In addition, the higher the rate of improvement in BDI, the lower the frequency of positive screening for ADHD by ASRS. This study showed that subjective ADHD symptoms were correlated with depressive states. Diagnostic evaluation of comorbid ADHD using self-report scales in a primary care setting should be made with caution.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  ADHD; comorbidity; depression

Year:  2021        PMID: 33799195     DOI: 10.1016/j.psychres.2021.113893

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  1 in total

1.  Working Conditions, Work Productivity, Quality of Life, and Depressive Symptoms in Undiagnosed Adults with and without Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms During the COVID-19 Pandemic.

Authors:  Toru Nakai; Toshinaga Tsuji; Hiroshi Tsuda; Takuma Sotodate; Yuki Namba; Tatsuhiro Uenishi; Katsuhiko Iwasaki; Kinya Kokubo; Hiroaki Tomita
Journal:  Neuropsychiatr Dis Treat       Date:  2022-07-29       Impact factor: 2.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.